Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 8,411 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares in the company, valued at $78,045.46. This trade represents a 79.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hims & Hers Health Trading Down 0.7%

Shares of NYSE HIMS traded down $0.23 during midday trading on Thursday, hitting $34.74. The company’s stock had a trading volume of 11,410,870 shares, compared to its average volume of 30,867,883. Hims & Hers Health, Inc. has a 12-month low of $23.97 and a 12-month high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market cap of $7.91 billion, a P/E ratio of 64.33, a price-to-earnings-growth ratio of 7.29 and a beta of 2.41. The business’s 50 day moving average is $42.69 and its two-hundred day moving average is $48.78.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims & Hers Health’s revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a share repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HIMS shares. BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. KeyCorp began coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Leerink Partnrs raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Bank of America boosted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $45.50.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of the company. Ethic Inc. acquired a new position in shares of Hims & Hers Health during the second quarter worth $348,000. Lake Hills Wealth Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter worth $277,000. Intellectus Partners LLC acquired a new position in Hims & Hers Health during the 2nd quarter valued at about $3,043,000. Occidental Asset Management LLC purchased a new stake in Hims & Hers Health in the second quarter valued at about $305,000. Finally, Dakota Wealth Management purchased a new stake in Hims & Hers Health in the second quarter valued at about $354,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.